Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom.

Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, García-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J.

Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018. Epub 2019 Apr 26.

PMID:
31128608
2.

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.

Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.

3.

Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI).

Hareendran A, Make BJ, Zaiser E, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2018 May 18;13:1633-1645. doi: 10.2147/COPD.S152087. eCollection 2018.

4.

GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).

Rebordosa C, Plana E, Aguado J, Thomas S, García-Gil E, Perez-Gutthann S, Castellsague J.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):126-133. doi: 10.1002/pds.4448. Epub 2018 May 8.

PMID:
29740896
5.

Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study.

Wise RA, Chapman KR, Scirica BM, Schoenfeld DA, Bhatt DL, Daoud SZ, Seoane B, Reisner C, Garcia Gil E.

Chronic Obstr Pulm Dis. 2018 Jan 24;5(1):5-15. doi: 10.15326/jcopdf.5.1.2017.0149.

6.

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.

Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558. doi: 10.2147/COPD.S143488. eCollection 2017.

7.

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.

Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.

Respir Res. 2017 May 30;18(1):106. doi: 10.1186/s12931-017-0583-0.

8.

E1a is an exogenous in vivo tumour suppressor.

Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, Pascual-Serra R, Ortega-Muelas M, Roche O, Marcos P, Garcia-Gil E, Fernandez-Aroca DM, Ramón Y Cajal S, Gutkind JS, Sanchez-Prieto R.

Cancer Lett. 2017 Jul 28;399:74-81. doi: 10.1016/j.canlet.2017.04.010. Epub 2017 Apr 15.

PMID:
28416454
9.

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.

D'Urzo A, Singh D, Garcia Gil E.

NPJ Prim Care Respir Med. 2017 Feb 24;27(1):13. doi: 10.1038/s41533-016-0009-3.

10.
11.

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.

Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E.

COPD. 2016 Dec;13(6):669-676. Epub 2016 May 9.

12.

MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.

Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, Sánchez-Prieto R.

Oncotarget. 2015 Dec 29;6(42):44095-107. doi: 10.18632/oncotarget.6574.

13.

Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies.

Chapman KR, Beck E, Alcaide D, Garcia Gil E.

Chronic Obstr Pulm Dis. 2015 Dec 22;3(1):435-445. doi: 10.15326/jcopdf.3.1.2015.0148.

14.

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.

Beeh KM, Watz H, Puente-Maestu L, de Teresa L, Jarreta D, Caracta C, Garcia Gil E, Magnussen H.

BMC Pulm Med. 2014 Dec 23;14:209. doi: 10.1186/1471-2466-14-209.

15.

A Comparison of The Reliability and Validity of the Four-Item and Six-Item NISCI Symptom Summary Scores.

Mocarski M, Trundell D, Zaiser E, Garcia Gil E, Lamarca R, Hareendran A.

Value Health. 2014 Nov;17(7):A601. doi: 10.1016/j.jval.2014.08.2081. Epub 2014 Oct 26. No abstract available.

16.

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.

Jones PW, Lamarca R, Chuecos F, Singh D, Agustí A, Bateman ED, de Miquel G, Caracta C, Garcia Gil E.

Eur Respir J. 2014 Nov;44(5):1156-65. doi: 10.1183/09031936.00038814. Epub 2014 Sep 18.

17.

ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.

Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF.

Clin Drug Investig. 2013 Dec;33(12):893-904. doi: 10.1007/s40261-013-0138-1.

PMID:
24085591
18.

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C; LAS-MD-35 study investigators.

Respir Med. 2013 Dec;107(12):1957-65. doi: 10.1016/j.rmed.2013.07.001. Epub 2013 Jul 31.

19.

Preference, satisfaction and errors with two dry powder inhalers in patients with COPD.

van der Palen J, Ginko T, Kroker A, van der Valk P, Goosens M, Padullés L, Seoane B, Rekeda L, Garcia Gil E.

Expert Opin Drug Deliv. 2013 Aug;10(8):1023-31. doi: 10.1517/17425247.2013.808186. Epub 2013 Jun 8.

PMID:
23745954
20.

Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity.

de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, Valero ML, Cimas FJ, Serrano-Oviedo L, Villas MV, Romero-Fernández J, Núñez MI, Sánchez-Prieto R.

Cancer Lett. 2013 Jul 10;335(1):66-74. doi: 10.1016/j.canlet.2013.01.050. Epub 2013 Feb 8.

PMID:
23403078
21.

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.

Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E.

Pulm Pharmacol Ther. 2012 Jun;25(3):248-53. doi: 10.1016/j.pupt.2012.03.008. Epub 2012 Apr 4. Erratum in: Pulm Pharmacol Ther. 2013 Apr;26(2):305.

PMID:
22497752
22.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E.

Eur Respir J. 2012 Oct;40(4):830-6. Epub 2012 Mar 22.

23.

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S.

Pulm Pharmacol Ther. 2012 Apr;25(2):193-9. doi: 10.1016/j.pupt.2012.02.002. Epub 2012 Feb 15.

PMID:
22366196
24.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators.

COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.

PMID:
22320148
25.

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.

Chest. 2012 Mar;141(3):745-752. doi: 10.1378/chest.11-0406. Epub 2011 Sep 8.

PMID:
21903737
26.

P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.

de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R.

Oncogene. 2012 Mar 1;31(9):1073-85. doi: 10.1038/onc.2011.321. Epub 2011 Aug 15.

PMID:
21841826
27.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med. 2010 Jun;104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. Epub 2009 Dec 30.

28.

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

Chanez P, Burge PS, Dahl R, Creemers J, Chuchalin A, Lamarca R, Garcia Gil E.

Pulm Pharmacol Ther. 2010 Feb;23(1):15-21. doi: 10.1016/j.pupt.2009.08.001. Epub 2009 Aug 14.

PMID:
19683590
29.

Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.

Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, Garcia Gil E.

Respir Med. 2009 Dec;103(12):1832-7. doi: 10.1016/j.rmed.2009.07.006. Epub 2009 Aug 3.

30.

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

Jansat JM, Lamarca R, Garcia Gil E, Ferrer P.

Int J Clin Pharmacol Ther. 2009 Jul;47(7):460-8.

PMID:
19640353
31.

[Microbiological study of post mortem lung biopsy in pediatric patients].

García-Gil E, Rojo F, Allende H, Campins M, Moraga-Llop FA, Ferrer A.

Enferm Infecc Microbiol Clin. 2000 Feb;18(2):66-70. Spanish.

PMID:
10721575
32.

[Clinical microbiology: is it a specialty in crisis?].

Falgueras T, Andonegui Navarro M, García Gil E, Moreno Vehí G, Osset Lladonosa J, Navarro Aguirre M, Arnal Millán J, Viñado Pérez B, Cardona Iglesias PJ, Giménez Pérez M, Padilla León E, Vallés Casanovas X, Pujol Riqué M, Vidal Lampurdanés C.

Enferm Infecc Microbiol Clin. 2000 Jan;18(1):45. Spanish. No abstract available.

PMID:
10721563

Supplemental Content

Loading ...
Support Center